Bristol Myers Squibb Company $BMY Stock: Westpac Banking Corp Cuts Holdings

by · The Cerbat Gem

Westpac Banking Corp trimmed its position in shares of Bristol Myers Squibb Company (NYSE:BMY – Free Report) by 16.2% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 142,655 shares of the biopharmaceutical company’s stock after selling 27,664 shares during the period. Westpac Banking Corp’s holdings in Bristol Myers Squibb were worth $8,902,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in BMY. Berger Financial Group Inc increased its stake in shares of Bristol Myers Squibb by 10.0% in the third quarter. Berger Financial Group Inc now owns 4,164 shares of the biopharmaceutical company’s stock worth $260,000 after acquiring an additional 380 shares during the last quarter. Tyche Wealth Partners LLC bought a new stake in shares of Bristol Myers Squibb in the 3rd quarter valued at approximately $530,000. Focus Advisor Solutions LLC increased its holdings in Bristol Myers Squibb by 82.2% in the third quarter. Focus Advisor Solutions LLC now owns 175,777 shares of the biopharmaceutical company’s stock worth $10,969,000 after buying an additional 79,299 shares during the last quarter. Checchi Capital Advisers LLC increased its holdings in Bristol Myers Squibb by 13.6% in the third quarter. Checchi Capital Advisers LLC now owns 9,936 shares of the biopharmaceutical company’s stock worth $620,000 after buying an additional 1,187 shares during the last quarter. Finally, Bluebird Wealth Management LLC bought a new position in Bristol Myers Squibb during the third quarter valued at approximately $200,000. 76.41% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Bristol Myers Squibb

In related news, SVP Phil M. Holzer sold 500 shares of the company’s stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total value of $33,750.00. Following the completion of the sale, the senior vice president owned 16,862 shares in the company, valued at $1,138,185. This represents a 2.88% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Julia Haller sold 3,800 shares of the firm’s stock in a transaction dated Thursday, November 5th. The stock was sold at an average price of $63.31, for a total value of $240,578.00. Following the sale, the director directly owned 30,279 shares in the company, valued at approximately $1,916,963.49. This represents a 11.15% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 0.05% of the company’s stock.

Analysts Set New Price Targets

Several research firms have weighed in on BMY. Morgan Stanley cut their target price on Bristol Myers Squibb from $41.00 to $40.00 and set an “underweight” rating on the stock in a report on Friday, October 30th. Piper Sandler cut their target price on shares of Bristol Myers Squibb from $82.00 to $78.00 and set an “overweight” rating for the company in a research report on Monday, October 26th. Zacks Research cut shares of Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 22nd. Wells Fargo & Company cut their price objective on Bristol Myers Squibb from $65.00 to $60.00 and set an “equal weight” rating for the company in a research report on Tuesday, October 13th. Finally, UBS Group downgraded shares of Bristol Myers Squibb from a “buy” rating to a “neutral” rating in a research note on Wednesday, August 5th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, sixteen have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Bristol Myers Squibb has an average rating of “Hold” and a consensus price target of $65.46.

Check Out Our Latest Stock Report on Bristol Myers Squibb

Bristol Myers Squibb Trading Down 2.1%

Shares of BMY stock opened at $58.33 on Friday. The company has a market capitalization of $119.23 billion, a P/E ratio of 12.93, a P/E/G ratio of 0.31 and a beta of 0.20. Bristol Myers Squibb Company has a 12-month low of $45.26 and a 12-month high of $68.64. The company has a quick ratio of 1.44, a current ratio of 1.59 and a debt-to-equity ratio of 1.79. The firm has a 50-day moving average price of $61.55 and a 200 day moving average price of $60.42.

Bristol Myers Squibb (NYSE:BMY – Get Free Report) last released its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $1.35 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.10 by $0.25. Bristol Myers Squibb had a return on equity of 60.48% and a net margin of 18.47%. The business had revenue of $13.07 billion during the quarter, compared to analysts’ expectations of $12.72 billion. During the same period in the previous year, the business posted $1.63 earnings per share. The firm’s revenue for the quarter was up 6.9% compared to the same quarter last year. Research analysts forecast that Bristol Myers Squibb Company will post 6.46 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, November 2nd. Investors of record on Friday, October 2nd were paid a dividend of $0.63 per share. The ex-dividend date of this dividend was Friday, October 2nd. This represents a $2.52 annualized dividend and a yield of 4.3%. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 55.88%.

Bristol Myers Squibb News Roundup

Investors following BMY have been watching these news items:

Bristol Myers Squibb Profile

(Free Report)

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops, manufactures and markets medicines. Its research and commercial activities focus on serious diseases, particularly cancer, blood disorders, immune-mediated conditions and cardiovascular disease. The company’s medicines include Opdivo and Yervoy for cancer, Eliquis for preventing and treating blood clots, and Orencia for certain autoimmune conditions. Its portfolio also includes treatments for hematologic diseases and other serious illnesses.

Featured Articles

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY – Free Report).